Adolor Corporation, the US-based biopharmaceutical company, has recently engaged Argenta Discovery to seek out new potential drug candidates in the field of pain management
David Jackson, Adolor's senior vice president of research and development, explained: "Over 40 million people in the United States alone suffer some form of loss of function due to chronic pain.
Yet it is a medical condition that is frequently treated inefficiently, either due to the limited effectiveness of currently available drugs or their side effects.
We are developing novel drug candidates that are intended to treat pain more effectively, but without the potential to become addictive and with less side effects." To help them with this task, Argenta will be using its extensive chemistry capabilities to synthesise and analyse a large number of compounds believed to activate the signalling transduction pathways involved in pain responses.
Argenta's team of highly experienced scientists, from both academic and pharmaceutical backgrounds, will then provide Adolor with any promising leads to test against receptor targets.
Commenting on behalf of Argenta, Tony Baxter, CEO, said: "We are very pleased to be collaborating with Adolor.
It has world-class expertise in the science of pain relief and considerable experience in the development of candidate drug compounds.
We can help Adolor by providing them with a wide range of candidate medicinal compounds to further their research into novel analgesics and pain-related therapeutics."
